Toll-like receptor 2 may be an effective therapeutic target for Parkinson’s disease because blocking Toll-like receptor 2 with functional inhibitory antibodies reduces the transmission of α-synuclein and the accumulation of α-synuclein between neurons and astrocytes between cells and improves nerve damage and neurodegenerative disease in mice with behavioral disorders of α-synuclein overexpression (138). The gene discussed is TLR2; the disease is Parkinson disease.